

Electronic Supplementary Information

Photocatalyst- and additive-free decarboxylative alkylation of *N*-aryl tetrahydroisoquinolines induced by visible light

Pengju Ma,^a Yufei Liu,^a Lingling Chen,^a Xu Zhao,^b Bo Yang,^a Junmin Zhang*^a

^aInternational Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, P. R. China

^bResearch Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China

Email: zhangjm@szu.edu.cn

Table of Contents

1. General Information.....	S2
2. Experimental Substrates	S3
2.1 Preparation of <i>N</i> -aryl tetrahydroisoquinolines.....	S3
2.2 Preparation of redox-active tetrachloro- <i>N</i> -hydroxyphthalimide esters	S7
3. Additional Experimental Optimization Experiments.....	S13
3.1 Screening of additional esters	S13
3.2 Screening of other solvents.....	S13
3.3 Screening of reaction time	S14
3.4 Screening of reaction concentration	S14
3.5 Screening of mole ratio between 1 and 2	S14
4. General Procedure for Visible-Light-Driven Decarboxylative Alkylation	S15
5. Gram-Scale Experiment.....	S16
6. Characterization of Products.....	S17
7. Unsuccessful Substrates.....	S38
8. Mechanistic Studies	S38
8.1 Radical trapping experiments	S38
8.2 Radical clock experiment	S40
8.3 UV-visible spectroscopic measurements.....	S41
9. Byproduct Analysis.....	S42
10. References.....	S43
11. ¹ H NMR and ¹³ C NMR Spectra	S44

1. General Information


Glassware and stir bars were dried in an oven at 110 °C for at least 12 h and then cooled in a desiccator cabinet prior to use. Optimization and substrate screens were performed in 10-mL Schlenk Storage Tubes (with High Vacuum Valves, SYNTHWARE, Mfr. No. F580010). Photochemical reactions were performed under the irradiation of Cree® XLamp® XT-E Royal Blue LEDs (3W, $\lambda_{\text{max}}=450$ nm) using a self-designed device. The reaction temperature was measured to be between 25 °C and 30 °C using this setup. Reactions were carried out under a nitrogen atmosphere with dry solvents under anhydrous conditions, unless otherwise noted. All other reactions were performed in round-bottom flasks sealed with rubber septa. Plastic syringes or glass pipets were used to transfer liquid reagents and solvents. Reactions were stirred magnetically using Teflon-coated, magnetic stir bars. Analytical thin-layer chromatography (TLC) was performed using plates pre-coated with 0.25 mm of 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm) supplied. TLC plates were visualized by exposure to ultraviolet light and/or iodine stain. Organic solutions were concentrated under reduced pressure using a rotary evaporator. Flash-column chromatography was performed on silica gel (Qingdao Haiyang Chemical Co., Ltd., 200–300 meshes) under pressure.

Nuclear magnetic resonance spectra were recorded at ambient temperature (unless otherwise stated) on a Bruker Avance III 500 MHz or 600 MHz NMR spectrometer. All values for proton chemical shifts are reported in parts per million (δ) and are calibrated using residual undeuterated solvent as an internal reference (CDCl_3 : $\delta = 7.26$ ppm). All values for carbon chemical shifts are reported in parts per million (δ) and are calibrated against the deuterated solvent peak (CDCl_3 : $\delta = 77.16$ ppm). NMR data are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintuplet, sext = sextet, sep = septet, dd = doublet of doublets, td = triplet of doublets, dq = doublet of quartets, m = multiplet, br = broad), coupling constant (Hz), and integration. High-resolution mass spectra were obtained using a liquid chromatography-electrospray ionization and Time-of-Flight mass spectrometer. Reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. Solvents for chromatography were used as supplied by Adamas-beta®.

2. Experimental Substrates

2.1 Preparation of *N*-aryl tetrahydroisoquinolines


(1)



The THIQ substrates **1a-1j**, **1o-1p**, **1r-1t** and **1v** were synthesized according to literature procedures.^[1]

A typical procedure is described as following: In a 100 mL high pressure schlenk tube were placed copper(I) iodide (190.5 mg, 1.0 mmol) and potassium phosphate (4.25 g, 20.0 mmol). The tube was evacuated and back filled with argon. 2-Propanol (10.0 mL), ethylene glycol (1.11 mL, 20.0 mmol), 1,2,3,4-tetrahydroisoquinoline (1.90 mL, 15.0 mmol) and aryl iodides (10.0 mmol) were added successively via syringes at room temperature. The reaction mixture was heated at 85–90 °C and kept for 24 h and then allowed to cool to room temperature. Ethyl acetate (50 mL) and water (80 mL) were then added. The aqueous layer was extracted by ethyl acetate (2×50 mL). The combined organic phases were washed with brine and dried over sodium sulfate. The solvent was removed via rotary evaporation and the remaining residue was purified via flash column chromatography (PE/EA, 50:1-20:1) to give the desired product.

(2)




The substrates **1k** and **1l** were synthesized according to literature procedures.^[2]

A 50 mL round bottomed flask was charged with Pd₂(dba)₃ (228.9 mg, 0.25 mmol), BINAP (311.3 mg, 0.50 mmol), and 15.0 mL of toluene. The resulting solution was degassed by sparging with argon for 10 min before refluxing at 110 °C for 15 min. The reaction mixture was allowed to cool to room temperature and sodium *tert*-butoxide (480.5 mg, 5.0 mmol), 1-bromonaphthalene (0.70 mL, 5.0 mmol) or 2-bromonaphthalene (1.04 g, 5.0 mmol), and 1,2,3,4-tetrahydroisoquinoline (1.25 mL, 10.0 mmol) were added. The resulting mixture was heated to reflux for 20 h before being cooled to room temperature and filtered through a pad of celite. The solvent was removed via rotary

evaporation, and the residue was purified by chromatography on silica gel using PE/EA (50:1-20:1) as the eluent to afford the desired product.


(3)



The substrates **1m** and **1n** were synthesized according to literature procedures.^[3]

A stirred absolute ethanol solution (50 mL) of compound 2-(2-bromoethyl)benzyl bromide (1.39g, 5.0 mmol), aniline (5.0 mmol) and potassium carbonate (13.8 g, 100.0 mmol) was refluxed for 8 h. The solvent was evaporated and the resulting residue was hydrolysed with water (20 mL) and extracted with ethyl acetate (3×25 mL). The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was then purified by column chromatography (silica gel; PE/EA, 50:1-20:1) to yield pure product.


(4)



The substrate **1q** was synthesized according to literature procedures.^[4]

To 1,2,3,4-tetrahydroisoquinoline (0.63 mL, 5.0 mmol) and 4-chloropyridine hydrochloride (750.1 mg, 5.0 mmol) in 6.0 mL of 1-methyl-2-pyrrolidinone was added triethylamine (1.74 mL, 12.5 mmol). The reaction mixture was slowly heated to 150 °C for 2 h. After cooling down, ethyl acetate was added and the mixture was washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was then purified by column chromatography (silica gel; PE/EA, 30:1-20:1) to yield pure product.

(5)




The substrate **1u** was synthesized according to a patented literature.^[5a]

To a stirred solution of 4-fluorobenzaldehyde (0.54 mL, 5.0 mmol) in dimethylsulfoxide (10.0 mL)


at room temperature was added potassium carbonate (1.12 g, 8.1 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.69 mL, 5.5 mmol). The reaction mixture was heated at 80 °C for 2 h. The reaction mixture was poured into cold water after completion of reaction. The mixture was extracted in ethyl acetate (2x30 mL). The combined organic layer was washed with water (30 mL) and brine (25 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography using PE/EA (50:1-30:1) as an eluent to afford the desired product.

(6)


The substrate **1w** was synthesized according to literature procedures.^[5b-d]



To a solution of 1,2,3,4-tetrahydro-9*H*-pyrido[3,4-*b*]indole (816.1 mg, 5.0 mmol) in CH₂Cl₂ (10 mL) was added slowly di-*tert*-butyl-dicarbonate (1.2 mL, 5.0 mmol) at 0 °C. After the addition was completed, the reaction mixture was allowed to reach room temperature and stirred for 3 h. And then the solvent was evaporated to get the crude product, which was crystallized from water to give the desired product as a white solid.




tert-Butyl 3,4-dihydro-1*H*-pyrido[3,4-*b*]indole-2(9*H*)-carboxylate (817.1 mg, 3.0 mmol) in THF was added to NaH (144.0 mg, 60 wt % mineral oil suspension, 3.6 mmol) in THF (0.25 M) at 0 °C. The mixture was warmed to room temperature, and MeI (0.28 mL, 4.5 mmol) was added. After 30 min, water was added, and the mixture was extracted with Et₂O. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and evaporated. Purification by column chromatography on silica gel, eluting with petrol-EtOAc (90:10), gave *tert*-butyl 9-methyl-1,3,4,9-tetrahydro-2*H*-pyrido[3,4-*b*]indole-2-carboxylate as an amorphous solid.



CF₃COOH (1.50 mL, 20.0 mmol) was added slowly to the solution of 9-methyl carbamate (572.8 mg, 2.0 mmol) in dichloromethane (0.25 M) at room temperature. The mixture was heated to


refluxing for 30 min. The reaction was diluted with H₂O and basified to pH 9–10 using NaOH (aq). The reaction extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel, eluting with CH₂Cl₂–MeOH (90:10), gave the desired product as a solid.



9-Methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-*b*]indole (186.3 mg, 1.0 mmol), iodobenzene (0.23 mL, 2.0 mmol), CuI (39.0 mg, 0.2 mmol) and anhydrous K₃PO₄ (1.27 g, 5.0 mmol) were added into a mixed solvent of ethylene glycol (2.0 mL) and isopropyl alcohol (4.0 mL) in a dried schlenk tube. The mixture was stirred at 90 °C under the protection of N₂ for 12 h. Then water (10 mL) was added and the aqueous suspension was extracted with DCM (3 x 20 mL). The organic phase was dried over anhydrous anhydrous sodium sulfate and the product was purified by column chromatography on silica gel (PE/EA, from 20 :1 to 5:1).


The *N*-Aryl tetrahydroisoquinoline substrates **1a-1l**, **1o**, and **1q-1w** have been previously reported, and all spectra data were identical to the literature.

Characterization data for *N*-aryl tetrahydroisoquinolines




2-([1,1'-biphenyl]-2-yl)-1,2,3,4-tetrahydroisoquinoline (**1m**).

General procedure was followed using 2-aminodiphenyl (846.1 mg, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (3/1) as an eluent, **1m** was obtained in 46% yield (656.4 mg) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 7.74–7.72 (m, 2H), 7.47–7.44 (m, 2H), 7.42–7.35 (m, 3H), 7.26–7.21 (m, 3H), 7.20–7.17 (m, 1H), 7.16–7.12 (m, 2H), 4.26 (s, 2H), 3.14 (t, *J* = 5.8 Hz, 2H), 2.66 (t, *J* = 5.8 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃): δ 150.2, 141.6, 135.2, 135.1, 134.9, 131.9, 128.90, 128.89, 128.4, 128.3, 126.8, 126.5, 126.2, 125.7, 122.5, 118.3, 52.6, 50.6, 29.1; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₂₁H₂₀N 286.1590, found 286.1596.



2-(2,6-dimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (**1n**).


General procedure was followed using 2,6-dimethoxyaniline (765.9 mg, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **1n** was obtained in 43% yield (579.1 mg) as a grey solid. ¹H NMR (500 MHz, CDCl₃): δ 7.19–7.14 (m, 3H), 7.09–7.05 (m, 2H), 6.61 (d, *J* = 8.5 Hz, 2H), 4.38 (s, 2H), 3.81 (s, 6H), 3.45 (t, *J* = 5.5 Hz, 2H), 2.97 (t, *J* = 5.5 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃): δ 157.5, 136.9, 135.4, 129.5, 129.1, 126.2, 125.5, 125.4, 124.9, 105.6, 56.1, 52.4, 48.9, 30.4; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₇H₂₀NO₂ 270.1489, found 270.1496.



2-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline (**1p**).

General procedure was followed using 3,4-dichloriodobenzene (2.73 g, 10.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (3/1) as an eluent, **1p** was obtained in 83% yield (2.31 g) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 7.30 (d, *J* = 9.0 Hz, 1H), 7.25–7.17 (m, 4H), 7.00 (d, *J* = 3.0 Hz, 1H), 6.77 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.38 (s, 2H), 3.53 (t, *J* = 6.0 Hz, 2H), 2.99 (t, *J* = 6.0 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃): δ 149.7, 134.7, 133.7, 132.9, 130.5, 128.5, 126.7, 126.6, 126.4, 120.7, 115.8, 114.0; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₅H₁₄Cl₂N 278.0498, found 278.0500.

2.2 Preparation of redox-active tetrachloro-*N*-hydroxyphthalimide esters




Redox-active esters were prepared according to the previously reported procedure^[6]. In short, a flame-dried round-bottom flask was charged with (if solid) carboxylic acid (5.0 mmol, 1.0 equiv), tetrachloro-*N*-hydroxyphthalimide (5.0 mmol, 1.50 g, 1.0 equiv) and DMAP (0.5 mmol, 61.1 mg, 0.1 equiv). CH₂Cl₂ was added (0.1 M), and the mixture was stirred vigorously. Carboxylic acid (5.0 mmol, 1.0 equiv) was added via syringe (if liquid). DIC (5.5 mmol, 0.85 mL, 1.1 equiv) was then

added dropwise via syringe, and the mixture was allowed to stir until the acid was consumed (determined by TLC). Typical reaction times were between 0.5 h and 12 h. The mixture was filtered (over Celite®, through a fritted funnel) and rinsed with additional CH₂Cl₂. The solvent was removed under reduced pressure, and purification by column chromatography afforded the desired TCNHPI redox-active ester. (Notes: Unless stated, no precautions were taken throughout the syntheses of the TCNHPI esters. No attempts were made to optimize for yield.)


The redox-active ester substrates **2d**, **2i-2j**, **2l-2m**, **2q-2s**, and **2v-2x** have been previously reported, and all spectra data were identical to the literature.

Characterization data for redox-active esters




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl butyrate (**2a**).

General procedure was followed using butyric acid (0.46 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2a** was obtained in 50% yield (0.93 g) as a white solid. ¹H NMR (600 MHz, CDCl₃): δ 2.63 (t, *J* = 7.2 Hz, 2H), 1.84–1.78 (m, 2H), 1.06 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 169.1, 157.6, 141.0, 130.5, 124.8, 32.8, 18.4, 13.5; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₂H₈Cl₄NO₄ 369.9202, found 369.9198.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl octanoate (**2b**).

General procedure was followed using octanoic acid (0.79 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2b** was obtained in 70% yield (1.49 g) as a white solid. ¹H NMR (600 MHz, CDCl₃): δ 2.65 (t, *J* = 7.5 Hz, 2H), 1.79–1.74 (m, 2H), 1.45–1.40 (m, 2H), 1.36–1.25 (m, 6H), 0.88 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 169.3, 157.6, 141.0, 130.5, 124.8, 31.6, 31.0, 28.9, 28.8, 24.8, 22.7, 14.2; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₆H₁₆Cl₄NO₄ 425.9828, found 425.9833.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl dodecanoate (**2c**).

General procedure was followed using lauric acid (1.00 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2c** was obtained in 64% yield (1.55 g) as a white solid. ¹H NMR (600 MHz, CDCl₃): δ 2.65 (t, *J* = 9.0 Hz, 2H), 1.80–1.74 (m, 2H), 1.46–1.40 (m, 2H), 1.34–1.26 (m, 14H), 0.87 (t, *J* = 8.4 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 169.3, 157.7, 141.0, 130.5, 124.9, 32.0, 31.0, 29.71, 29.69, 29.462, 29.458, 29.2, 28.9, 24.8, 22.8, 14.2; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₂₀H₂₄Cl₄NO₄ 482.0454, found 482.0457.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl 2-cyclohexylacetate (**2e**).

General procedure was followed using cyclohexylacetic acid (0.71 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2e** was obtained in 58% yield (1.23 g) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 2.53 (d, *J* = 6.5 Hz, 2H), 1.96–1.86 (m, 3H), 1.75 (dt, *J* = 13.5, 3.5 Hz, 2H), 1.70–1.65 (m, 1H), 1.35–1.27 (m, 2H), 1.19 (tt, *J* = 12.5, 3.5 Hz, 1H), 1.13–1.05 (m, 2H); ¹³C NMR (126 MHz, CDCl₃): δ 168.5, 157.7, 141.1, 130.6, 124.9, 38.7, 35.2, 32.9, 26.1, 26.0; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₆H₁₄Cl₄NO₄ 423.9671, found 423.9679.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl 2-phenylacetate (**2f**).

General procedure was followed using phenylacetic acid (0.68 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2f** was obtained in 74% yield (1.55 g) as a white solid. ¹H NMR (600 MHz, CDCl₃): δ 7.40–7.35 (m, 4H), 7.34–7.31 (m, 1H), 3.99 (s, 2H); ¹³C NMR (151 MHz, CDCl₃): δ 167.3, 157.5, 141.2, 131.3, 130.6, 129.3, 129.1, 128.0, 124.8, 37.7; HRMS (ESI-TOF) *m/z* [M+H]⁺ calcd for C₁₆H₈Cl₄NO₄ 417.9202, found 417.9197.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl 2-(4-methoxyphenyl)acetate (**2g**).

General procedure was followed using 4-methoxyphenylacetic acid (0.83 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using DCM/EA (30/1) as an eluent, **2g** was obtained in 76% yield (1.71 g) as a white solid. $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 7.28–7.26 (m, 2H), 6.90–6.87 (m, 2H), 3.92 (s, 2H), 3.79 (s, 3H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3): δ 167.5, 159.3, 157.5, 141.1, 130.5, 130.4, 124.8, 123.2, 114.4, 55.4, 36.9; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{10}\text{Cl}_4\text{NO}_5$ 447.9308, found 447.9302.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl (*tert*-butoxycarbonyl)glycinate (**2h**).

General procedure was followed using *N*-Boc glycine (0.88 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using DCM/EA (20/1) as an eluent, **2h** was obtained in 51% yield (1.17 g) as a white solid. $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 5.10 (s, 1H), 4.35–4.21 (m, 2H), 1.50–1.46 (m, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3): δ 166.9, 157.2, 155.4, 141.3, 130.7, 124.7, 81.0, 40.4, 28.4; HRMS (ESI-TOF) m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{12}\text{Cl}_4\text{N}_2\text{O}_6\text{Na}$ 478.9342, found 478.9346.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl cyclobutanecarboxylate (**2k**).

General procedure was followed using cyclobutane carboxylic acid (0.48 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2k** was obtained in 79% yield (1.51 g) as a white solid. $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 3.54–3.47 (m, 1H), 2.54–2.46 (m, 2H), 2.45–2.38 (m, 2H), 2.16–2.00 (m, 2H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3): δ 171.1, 157.8, 141.1, 130.6, 124.9, 35.0, 25.5, 18.9; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_7\text{Cl}_4\text{NO}_4\text{Na}$ 403.9021, found 403.9018.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl cycloheptanecarboxylate (**2n**).

General procedure was followed using cycloheptane carboxylic acid (0.71 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2n** was obtained in 60% yield (1.28 g) as a white solid. ^1H NMR (500 MHz, CDCl_3): δ 2.92–2.86 (m, 1H), 2.14–2.08 (m, 2H), 1.90–1.77 (m, 4H), 1.64–1.53 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3): δ 172.5, 157.9, 141.0, 130.5, 124.9, 42.1, 30.8, 28.3, 26.3; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{Cl}_4\text{NO}_4$ 423.9671, found 423.9663.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl cyclohex-3-ene-1-carboxylate (**2o**).

General procedure was followed using cyclohexene carboxylic acid (0.58 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2o** was obtained in 74% yield (1.51 g) as a white solid. ^1H NMR (600 MHz, CDCl_3): δ 5.76–5.74 (m, 1H), 5.72–5.69 (m, 1H), 3.02–2.97 (m, 1H), 2.47–2.38 (m, 2H), 2.26–2.13 (m, 3H), 1.93–1.86 (m, 1H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.4, 157.8, 141.1, 130.5, 126.9, 124.9, 124.3, 36.9, 27.2, 25.0, 23.9; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{10}\text{Cl}_4\text{NO}_4$ 407.9358, found 407.9365.




4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl 4-oxocyclohexane-1-carboxylate (**2p**).

General procedure was followed using 4-oxocyclohexane carboxylic acid (0.71 g, 5.0 mmol, 1.0 equiv). Purification through column chromatography using DCM/EA (30/1) as an eluent, **2p** was obtained in 72% yield (1.53 g) as a white solid. ^1H NMR (500 MHz, CDCl_3): δ 3.23–3.18 (m, 1H), 2.61 (dt, $J = 15.0, 6.3$ Hz, 2H), 2.47–2.41 (m, 2H), 2.39–2.33 (m, 2H), 2.31–2.23 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 208.7, 170.2, 157.7, 141.4, 130.7, 124.8, 39.2, 38.0, 28.3; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{10}\text{Cl}_4\text{NO}_5$ 423.9308, found 423.9307.



4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl pivalate (**2t**).

General procedure was followed using pivalic acid (0.57 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2t** was obtained in 78% yield (1.50 g) as a white solid. ^1H NMR (500 MHz, CDCl_3): δ 1.42 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3): δ 174.0, 157.8, 141.1, 130.5, 124.9, 38.6, 27.1; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{10}\text{Cl}_4\text{NO}_4$ 383.9358, found 383.9354.





4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl 2,2-dimethylbutanoate (**2u**).

General procedure was followed using 2,2-dimethylbutyric acid (0.63 mL, 5.0 mmol, 1.0 equiv). Purification through column chromatography using PE/DCM (1/1) as an eluent, **2u** was obtained in 74% yield (1.48 g) as a white solid. ^1H NMR (500 MHz, CDCl_3): δ 1.77 (q, $J = 7.5$ Hz, 2H), 1.37 (s, 6H), 1.03 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 173.5, 157.9, 141.1, 130.5, 124.9, 42.8, 33.6, 24.8, 9.3; HRMS (ESI-TOF) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{12}\text{Cl}_4\text{NO}_4$ 397.9515, found 397.9513.

3. Additional Experimental Optimization Experiments


3.1 Screening of additional esters^a



entry	2q	yield (%) ^b
1	2qa	94 ^c
2	2qb	—
3	2qc	—
4	2qd	trace

^aReaction conditions: **1** (0.20 mmol), **2q** (0.24 mmol) in anhydrous DMF (2.0 mL) under N₂ at room temperature for 24 hours under irradiation of blue LEDs (3 W). ^bYields of **3** were determined based on ¹H NMR analysis of the crude reaction mixture using 1,3,5-trimethoxybenzene as an internal standard. ^cIsolated yield after silica gel chromatography.


3.2 Screening of other solvents^a



entry	solvent	yield (%) ^b	entry	solvent	yield (%) ^b
1	hexane	16	6	TBME	trace
2	ethyl acetate	15	7	DME	20
3	MeOH	14	8	CHCl ₃	18
4	THF	16	9	acetone	58
5	1,4-dioxane	trace	10	NMP	88

^aReaction conditions: **1a** (0.20 mmol), **2q** (0.24 mmol) in anhydrous solvent (2.0 mL) under N₂ at room temperature for 24 hours under irradiation of blue LEDs (3 W). ^bIsolated yield after silica gel chromatography. THF = tetrahydrofuran, TBME = *tert*-butyl methyl ether, DME = 1,2-dimethoxyethane, NMP = *N*-methyl-2-pyrrolidinone.


3.3 Screening of reaction time^a



entry	reaction time (h)	yield (%) ^b
1	12	91
2	24	94
3	36	93
4	48	94

^aReaction conditions: **1a** (0.20 mmol), **2q** (0.24 mmol) in anhydrous DMF (2.0 mL) under N₂ at room temperature for given hours under irradiation of blue LEDs (3 W). ^bIsolated yield after silica gel chromatography.


3.4 Screening of reaction concentration^a



entry	X (mL)	yield (%) ^b
1	1.0	93
2	2.0	94
3	4.0	94

^aReaction conditions: **1a** (0.20 mmol), **2q** (0.24 mmol) in anhydrous DMF under N₂ at room temperature for 24 hours under irradiation of blue LEDs (3 W). ^bIsolated yield after silica gel chromatography.


3.5 Screening of mole ratio between **1** and **2**^a



entry	1a (mmol)	2q (mmol)	yield (%) ^b
1	0.20	0.20	83%
2	0.20	0.24	94%
3	0.20	0.30	90%
4	0.30	0.20	87%


^aReaction conditions: **1a** and **2q** in anhydrous DMF (2.0 mL) under N₂ at room temperature for 24 hours under irradiation of blue LEDs (3 W). ^bIsolated yield after silica gel chromatography.

4. General Procedure for Visible-Light-Driven Decarboxylative alkylation




A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1** (0.20 mmol, 1.0 equiv), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2** (0.24 mmol, 1.2 equiv) under air. The tube was evacuated and backfilled with N₂ for 3 times (3 × 5 min). Degassed DMF (2.0 mL) was added by syringe under N₂. The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (PE/DCM or DCM/EA) to give the desired product **3** or **4**.

5. Gram-Scale Experiment




A 100-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (1.05g, 5.0 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2q** (2.21g, 5.35 mmol) under air. The tube was evacuated and backfilled with N₂ for 3 times (3 × 5 min). Degassed DMF (30.0 mL) was added by syringe under N₂. The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 100.0 mL ethyl acetate and 20.0 mL water. The organic layer was separated and the aqueous layer extracted with 50.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (DCM/EA=30:1) to give the desired product **3q** (1.28g, 87% yield) as a colorless oil.

6. Characterization of Products 3 and 4




2-phenyl-1-propyl-1,2,3,4-tetrahydroisoquinoline (**3a**). **3a** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2a** (89.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3a** (23.1 mg, 46% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.22 (m, 2H), 7.18–7.10 (m, 4H), 6.88 (d, *J* = 8.0 Hz, 2H), 6.72 (t, *J* = 7.3 Hz, 1H), 4.66 (t, *J* = 7.3 Hz, 1H), 3.63 (ddd, *J* = 12.8, 8.0, 4.8 Hz, 1H), 3.59 (dt, *J* = 12.5, 5.5 Hz, 1H), 3.02 (ddd, *J* = 15.8, 8.3, 5.5 Hz, 1H), 2.86 (dt, *J* = 16.0, 5.5 Hz, 1H), 1.95 (dddd, *J* = 13.5, 10.5, 7.5, 5.0 Hz, 1H), 1.69 (dddd, *J* = 13.8, 10.3, 7.0, 6.0 Hz, 1H), 1.54–1.37 (m, 2H), 0.95 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 149.8, 139.3, 135.1, 129.4, 128.6, 127.4, 126.5, 125.8, 117.0, 113.8, 59.1, 42.0, 39.2, 27.3, 20.2, 14.3.

Spectra data were identical to the literature.^[7]



1-heptyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3b**). **3b** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2b** (102.5 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3b** (18.4 mg, 30% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.26–7.21 (m, 2H), 7.18–7.09 (m, 4H), 6.87 (d, *J* = 8.5 Hz, 2H), 6.71 (t, *J* = 7.3 Hz, 1H), 4.64 (t, *J* = 7.0 Hz, 1H), 3.63 (ddd, *J* = 12.8, 8.3, 5.0 Hz, 1H), 3.59 (dt, *J* = 13.0, 5.8 Hz, 1H), 3.02 (ddd, *J* = 16.0, 8.0, 5.5 Hz, 1H), 2.85 (dt, *J* = 16.0, 5.5 Hz, 1H), 2.00–1.92 (m, 1H), 1.73–1.66 (m, 1H), 1.52–1.44 (m, 1H), 1.42–1.34 (m, 2H), 1.32–1.21 (m, 7H), 0.87 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 149.8, 139.4, 135.1, 129.4, 128.6, 127.5, 126.5, 125.8, 117.0, 113.8, 59.4, 41.9, 37.0, 32.0, 29.8, 29.4, 27.2, 27.1, 22.8, 14.2.


Spectra data were identical to the literature.^[8]




2-phenyl-1-undecyl-1,2,3,4-tetrahydroisoquinoline (**3c**). **3c** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2c** (116.0 mg, 0.24 mmol) as starting materials.

Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3c** (30.5 mg, 42% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.22 (m, 2H), 7.17–7.09 (m, 4H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.71 (t, *J* = 7.3 Hz, 1H), 4.64 (t, *J* = 7.0 Hz, 1H), 3.63 (ddd, *J* = 12.5, 8.0, 5.0 Hz, 1H), 3.59 (dt, *J* = 12.5, 5.5 Hz, 1H), 3.02 (ddd, *J* = 16.0, 8.0, 5.5 Hz, 1H), 2.85 (dt, *J* = 16.0, 5.5 Hz, 1H), 1.99–1.92 (m, 1H), 1.73–1.66 (m, 1H), 1.52–1.44 (m, 1H), 1.42–1.36 (m, 1H), 1.32–1.22 (m, 16H), 0.89 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 149.8, 139.4, 135.1, 129.4, 128.6, 127.5, 126.5, 125.8, 117.0, 113.8, 59.4, 41.9, 37.0, 32.08, 32.07, 29.80, 29.78, 29.77, 29.52, 29.49, 27.2, 27.0, 22.8, 14.3.

Spectra data were identical to the literature.^[8]




2-phenyl-1-(4-phenylbutyl)-1,2,3,4-tetrahydroisoquinoline (**3d**). **3d** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2d** (110.7 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3d** (26.6 mg, 39% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.29–7.22 (m, 4H), 7.20–7.12 (m, 6H), 7.10–7.06 (m, 1H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.73 (d, *J* = 7.3 Hz, 1H), 4.64 (t, *J* = 7.0 Hz, 1H), 3.63 (ddd, *J* = 12.8, 8.3, 5.0 Hz, 1H), 3.59 (dt, *J* = 13.0, 5.8 Hz, 1H), 3.02 (ddd, *J* = 15.8, 8.0, 5.8 Hz, 1H), 2.85 (dt, *J* = 15.5, 5.5 Hz, 1H), 2.64–2.56 (m, 2H), 2.04–1.97 (m, 1H), 1.78–1.70 (m, 1H), 1.69–1.63 (m, 2H), 1.59–1.51 (m, 1H), 1.50–1.42 (m, 1H); ¹³C NMR (126 MHz, CDCl₃): δ 149.8, 142.7, 139.2, 135.1, 129.4, 128.6, 128.5, 128.4, 127.4, 126.5, 125.9, 125.8, 117.1, 113.9, 59.3, 42.0, 36.7, 36.0, 31.7, 27.2, 26.7; HRMS (ESI-TOF) *m/z* [*M* + *H*]⁺ calcd for C₂₅H₂₈N 342.2216, found 342.2226.




1-(cyclohexylmethyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3e**). **3e** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2e** (102.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3e** (34.2 mg, 56% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.21 (m, 2H), 7.18–7.13

(m, 2H), 7.11–7.08 (m, 2H), 6.89 (d, $J = 8.0$ Hz, 2H), 6.72 (t, $J = 7.3$ Hz, 1H), 4.80 (t, $J = 7.3$ Hz, 1H), 3.63 (dd, $J = 7.0, 5.0$ Hz, 2H), 3.02 (dt, $J = 16.0, 7.5$ Hz, 1H), 2.80 (dt, $J = 16.0, 5.0$ Hz, 1H), 1.94–1.87 (m, 2H), 1.77–1.71 (m, 2H), 1.69–1.64 (m, 2H), 1.56–1.50 (m, 1H), 1.47–1.37 (m, 1H), 1.33–1.14 (m, 3H), 1.10–0.95 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 150.0, 139.7, 135.0, 129.4, 128.8, 127.4, 126.4, 125.8, 117.2, 114.2, 56.4, 44.6, 41.7, 34.6, 33.80, 33.76, 26.8, 26.6, 26.4, 26.3. Spectra data were identical to the literature.^[9]



1-benzyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3f**). **3f** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2f** (100.6 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3f** (27.5 mg, 46% yield) as a white syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.25–7.21 (m, 4H), 7.19–7.13 (m, 3H), 7.07–7.02 (m, 3H), 6.85 (d, $J = 8.0$ Hz, 2H), 6.76–6.72 (m, 2H), 4.91 (t, $J = 6.8$ Hz, 1H), 3.66 (ddd, $J = 12.3, 7.8, 5.0$ Hz, 1H), 3.56 (ddd, $J = 12.0, 6.5, 5.5$ Hz, 1H), 3.27 (dd, $J = 13.5, 6.0$ Hz, 1H), 3.01 (dd, $J = 13.5, 7.5$ Hz, 1H), 2.76 (dt, $J = 16.0, 5.9$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.5, 139.0, 137.8, 135.2, 129.9, 129.4, 128.4, 128.3, 127.8, 126.7, 126.4, 125.6, 117.3, 113.8, 61.6, 42.6, 42.3, 27.6.


Spectra data were identical to the literature.^[7, 9 and 10]




1-(4-methoxybenzyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3g**). **3g** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2g** (107.8 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=50:1) afforded **3g** (64.6 mg, 98% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.28–7.25 (m, 2H), 7.19–7.14 (m, 2H), 7.12–7.06 (m, 1H), 6.94 (d, $J = 8.5$ Hz, 2H), 6.88 (d, $J = 8.0$ Hz, 2H), 6.80–6.78 (m, 3H), 6.76 (t, $J = 7.3$ Hz, 1H), 4.89 (t, $J = 6.5$ Hz, 1H), 3.80 (s, 3H), 3.65 (ddd, $J = 12.0, 7.5, 5.0$ Hz, 1H), 3.55 (dt, $J = 12.5, 5.8$ Hz, 1H), 3.21 (dd, $J = 13.5, 5.5$ Hz, 1H), 3.03–2.96 (m, 2H), 2.75 (dt, $J = 15.5, 6.0$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 158.3, 149.5, 137.8, 135.2, 131.0, 130.8, 129.4, 128.3,

127.8, 126.7, 125.6, 117.2, 113.69, 113.67, 61.7, 55.3, 42.3, 41.6, 27.7.

Spectra data were identical to the literature.^[9a, 10e and 11]




tert-butyl ((2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)carbamate (**3h**). **3h** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2h** (109.9 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **3h** (62.3 mg, 92% yield) as a white syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.29–7.13 (m, 6H), 7.00 (d, *J* = 8.0 Hz, 2H), 6.81 (t, *J* = 7.3 Hz, 1H), 4.93–4.56 (m, 2H), 3.70–3.32 (m, 4H), 3.08–3.02 (m, 1H), 2.86–2.74 (m, 1H), 1.49 (s, 9H); ¹³C NMR (126 MHz, CDCl₃): δ 156.2, 150.1, 135.7, 135.4, 129.4, 128.8, 127.7, 127.0, 126.2, 118.3, 114.9, 59.1, 45.0, 41.6, 28.5, 26.4; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₁H₂₇N₂O₂ 339.2067, found 339.2069.




1-isopropyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3i**). **3i** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2i** (89.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3i** (47.8 mg, 95% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.27–7.22 (m, 2H), 7.20–7.12 (m, 4H), 6.89 (d, *J* = 8.0 Hz, 2H), 6.71 (t, *J* = 7.3 Hz, 1H), 4.41 (d, *J* = 8.0 Hz, 1H), 3.76 (d, *J* = 12.0, 6.0 Hz, 1H), 3.49 (dt, *J* = 12.0, 7.0 Hz, 1H), 3.07–2.97 (m, 2H), 2.21–2.11 (m, 1H), 1.10 (d, *J* = 7.0 Hz, 3H), 0.97 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 150.2, 137.9, 135.5, 129.2, 128.4, 128.3, 126.7, 125.4, 116.6, 113.3, 64.7, 43.1, 34.5, 27.5, 20.8, 20.2.

Spectra data were identical to the literature.^[9b, 10a, 10e and 12]




1-(heptan-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3j**). **3j** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2j** (102.5 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3j** (51.7 mg, 84% yield, dr = 1:1) as a colorless oil (two pairs of diastereomers, which can not be separated

by silica gel column chromatography). ^1H NMR (500 MHz, CDCl_3): δ 7.23–7.19 (m, 2H), 7.18–7.09 (m, 4H), 6.87 (d, $J = 8.5$ Hz, 2H), 6.69 (t, $J = 7.0$ Hz, 1H), 4.62 (d, $J = 8.5$, 1H), 4.61 (d, $J = 9.0$, 1H), 3.72 (dt, $J = 12.0$, 6.5 Hz, 1H), 3.53 (dt, $J = 12.5$, 6.8 Hz, 1H), 3.03–2.94 (m, 2H), 1.84–1.75 (m, 1H), 1.64–1.40 (m, 3H), 1.37–1.16 (m, 5H), 0.91–0.84 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3): δ 150.5, 150.4, 138.71, 138.70, 135.44, 135.43, 129.20, 129.18, 128.49, 128.47, 128.09, 128.08, 126.6, 125.39, 125.38, 116.81, 116.77, 113.9, 113.8, 60.82, 60.76, 45.3, 44.8, 43.2, 31.7, 29.44, 29.43, 29.2, 28.7, 27.1, 23.3, 23.2, 22.9, 22.6, 14.3, 14.2, 11.7, 10.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{30}\text{N}$ 308.2373, found 308.2375.



1-cyclobutyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3k**). **3k** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2k** (91.9 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3k** (51.1 mg, 97% yield) as a colorless syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.24 (t, $J = 8.0$ Hz, 2H), 7.19–7.10 (m, 4H), 6.95 (d, $J = 8.0$ Hz, 2H), 6.74 (t, $J = 7.3$ Hz, 1H), 4.62 (d, $J = 8.0$ Hz, 1H), 3.66–3.58 (m, 2H), 3.02 (dt, $J = 16.0$, 7.5 Hz, 1H), 2.90–2.82 (m, 1H), 2.77 (dt, $J = 16.0$, 4.8 Hz, 1H), 1.99–1.86 (m, 4H), 1.82–1.68 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 150.4, 137.7, 134.9, 129.3, 128.8, 127.3, 126.6, 125.7, 117.4, 114.6, 63.4, 42.1, 41.8, 27.6, 27.1, 26.8, 18.2.


Spectra data were identical to the literature.^[8, 9b and 12]



1-cyclopentyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3l**). **3l** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2l** (95.3 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3l** (52.7 mg, 95% yield) as a white syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.25–7.20 (m, 2H), 7.18–7.11 (m, 4H), 6.91 (d, $J = 8.0$ Hz, 2H), 6.70 (t, $J = 7.3$ Hz, 1H), 4.56 (d, $J = 9.0$ Hz, 1H), 3.75 (ddd, $J = 13.0$, 8.5, 5.5 Hz, 1H), 3.66 (dt, $J = 13.0$, 5.8 Hz, 1H), 3.05 (ddd, $J = 16.3$, 8.4, 6.5 Hz, 1H), 2.90 (dt, $J = 16.5$, 5.5 Hz, 1H), 2.39–2.30 (m, 1H), 1.90–1.84 (m, 1H), 1.76–1.61 (m, 3H), 1.59–1.37 (m, 4H); ^{13}C NMR


(126 MHz, CDCl₃): δ 150.1, 139.0, 135.0, 129.3, 128.7, 127.8, 126.6, 125.5, 116.9, 114.0, 62.9, 47.3, 42.1, 31.2, 30.8, 26.9, 25.3, 24.6.

Spectra data were identical to the literature.^[8 and 9b]




1-cyclohexyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3m**). **3m** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2m** (98.7 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3m** (57.1 mg, 98% yield) as a white syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.26–7.22 (m, 2H), 7.20–7.13 (m, 3H), 7.09 (d, J = 7.5 Hz, 1H), 6.88 (d, J = 8.5 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 4.45 (d, J = 8.0 Hz, 1H), 3.75 (dt, J = 12.0, 6.0 Hz, 1H), 3.49 (ddd, J = 12.0, 7.5, 6.5 Hz, 1H), 3.05 (ddd, J = 17.0, 8.5, 7.0 Hz, 1H), 3.01 (dt, J = 16.0, 6.5 Hz, 1H), 2.00 (dd, J = 11.5, 1.5 Hz, 1H), 1.81–1.61 (m, 5H), 1.24–1.03 (m, 5H); ¹³C NMR (126 MHz, CDCl₃): δ 150.1, 138.0, 135.4, 129.2, 128.5, 128.3, 126.7, 125.3, 116.4, 113.1, 63.9, 44.2, 43.1, 31.1, 30.8, 27.5, 26.8, 26.6, 26.5.

Spectra data were identical to the literature.^[8, 9, 10e and 12]




1-cycloheptyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3n**). **3n** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2n** (102.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3n** (58.0 mg, 95% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.22 (m, 2H), 7.20–7.12 (m, 4H), 6.86 (d, J = 8.5 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 4.48 (d, J = 8.5 Hz, 1H), 3.74 (dt, J = 12.0, 5.8 Hz, 1H), 3.46 (ddd, J = 12.0, 8.5, 6.0 Hz, 1H), 3.07 (ddd, J = 16.0, 8.0, 6.0 Hz, 1H), 3.00 (dt, J = 16.0, 6.0 Hz, 1H), 2.00–1.89 (m, 2H), 1.78–1.72 (m, 2H), 1.68–1.57 (m, 2H), 1.55–1.45 (m, 3H), 1.44–1.30 (m, 4H); ¹³C NMR (126 MHz, CDCl₃): δ 150.2, 138.7, 135.5, 129.2, 128.3, 128.2, 126.6, 125.4, 116.5, 113.1, 64.0, 46.4, 43.5, 32.5, 31.2, 28.9, 27.9, 27.7, 27.1, 26.5.

Spectra data were identical to the literature.^[9b]




1-(cyclohex-3-en-1-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3o**). **3o** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2o** (98.2 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3o** (55.6 mg, 96% yield, dr = 1:1) as a colorless oil (two pairs of diastereomers, which can not be separated by silica gel column chromatography). ¹H NMR (500 MHz, CDCl₃): δ 7.27–7.23 (m, 2H), 7.22–7.11 (m, 4H), 6.90 (d, *J* = 9.0 Hz, 2H), 6.71 (dd, *J* = 13.5, 7.0 Hz, 1H), 5.72–5.63 (m, 2H), 4.55 (d, *J* = 8.0 Hz, 0.54H), 4.52 (d, *J* = 8.5 Hz, 0.46H), 3.80–3.74 (m, 1H), 3.59–3.49 (m, 1H), 3.09–2.99 (m, 2H), 2.33–1.87 (m, 6H), 1.50–1.36 (m, 1H); ¹³C NMR (126 MHz, CDCl₃): δ 150.2, 150.1, 137.9, 137.7, 135.5, 135.3, 129.3, 129.2, 128.6, 128.5, 128.4, 128.1, 127.3, 126.9, 126.84, 126.79, 126.7, 126.4, 125.5, 125.3, 116.73, 116.65, 113.4, 113.2, 63.3, 62.9, 43.2, 42.7, 40.5, 39.9, 30.0, 29.6, 27.4, 27.2, 26.7, 26.3, 26.0, 25.4; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₁H₂₄N 290.1903, found 290.1911.




4-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)cyclohexan-1-one (**3p**). **3p** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2p** (102.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **3p** (53.1 mg, 87% yield) as a white syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.26–7.15 (m, 5H), 7.09 (d, *J* = 7.5 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.73 (t, *J* = 7.3 Hz, 1H), 4.54 (d, *J* = 8.5 Hz, 1H), 3.79 (dt, *J* = 12.0, 6.3 Hz, 1H), 3.52 (dt, *J* = 12.0, 7.0 Hz, 1H), 3.04 (t, *J* = 6.5 Hz, 2H), 2.44–2.29 (m, 4H), 2.28–2.20 (m, 2H), 2.10–2.04 (m, 1H), 1.70–1.53 (m, 2H); ¹³C NMR (126 MHz, CDCl₃): δ 211.8, 149.8, 137.0, 135.3, 129.4, 128.6, 128.2, 127.2, 125.7, 117.3, 113.6, 62.6, 43.3, 42.7, 41.2, 40.8, 30.6, 30.2, 27.4.

Spectra data were identical to the literature.^[12]




2-phenyl-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**3q**). **3q** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **3q** (55.2 mg, 94% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.21 (m, 2H), 7.20–7.13 (m, 3H), 7.08 (d, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 8.0 Hz, 2H), 6.72 (t, *J* = 7.0 Hz, 1H), 4.45 (d, *J* = 8.5 Hz, 1H), 4.02–3.96 (m, 2H), 3.74 (dt, *J* = 12.0, 6.5 Hz, 1H), 3.54 (dt, *J* = 13.0, 6.5 Hz, 1H), 3.33 (td, *J* = 12.0, 2.0 Hz, 1H), 3.25 (td, *J* = 11.8, 2.5 Hz, 1H), 3.07–2.95 (m, 2H), 2.03–1.95 (m, 1H), 1.88–1.84 (m, 1H), 1.59–1.44 (m, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 150.0, 136.9, 135.3, 129.3, 128.6, 128.4, 127.0, 125.5, 117.0, 113.5, 68.5, 68.0, 63.3, 42.9, 41.6, 31.1, 31.0, 27.2. Spectra data were identical to the literature.^[9b and 12]




tert-butyl 4-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)piperidine-1-carboxylate (**3r**). **3r** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2r** (122.9 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **3r** (73.0 mg, 93% yield) as a white syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.25–7.20 (m, 2H), 7.19–7.13 (m, 3H), 7.06 (d, *J* = 7.5 Hz, 1H), 6.86 (d, *J* = 8.5 Hz, 2H), 6.71 (t, *J* = 7.3 Hz, 1H), 4.45 (d, *J* = 8.5 Hz, 1H), 4.15–4.11 (m, 2H), 3.74 (dt, *J* = 12.0, 6.5 Hz, 1H), 3.51 (dt, *J* = 12.0, 7.0 Hz, 1H), 3.06–2.96 (m, 2H), 2.61 (t, *J* = 12.3 Hz, 1H), 2.53 (t, *J* = 10.5 Hz, 1H), 1.94–1.85 (m, 2H), 1.68–1.63 (m, 2H), 1.45 (s, 9H), 1.38–1.30 (m, 1H); ¹³C NMR (126 MHz, CDCl₃): δ 154.9, 149.9, 137.0, 135.3, 129.3, 128.6, 128.4, 127.0, 125.5, 117.0, 113.4, 79.4, 63.1, 43.0, 42.7, 30.1, 29.9, 28.6, 27.3, 21.2, 14.3.

Spectra data were identical to the literature.^[9b and 12]




2-phenyl-1-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline (**3s**). **3s** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2s** (103.9 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=3:1) afforded **3s'** (13.8 mg, 22% yield) as a colorless oil and **3s''** (13.2 mg, 21% yield) as a colorless oil. (**3s'**): ¹H NMR (500 MHz, CDCl₃): δ 7.31–7.26 (m, 2H), 7.21–7.14 (m, 3H), 7.12 (td, *J* = 7.5, 1.0 Hz, 1H), 7.00–6.91 (m, 4H), 6.86 (d, *J* = 7.0 Hz, 2H), 6.75 (t, *J* = 7.3 Hz, 1H), 6.61 (d, *J* = 8.0 Hz, 1H), 4.79 (d, *J* = 7.0 Hz, 1H), 3.61 (dt, *J* = 11.5, 5.5 Hz, 1H), 3.41–3.31 (m, 2H), 2.66 (dt, *J* = 16.0, 5.5 Hz, 1H), 2.02 (ddd, *J* = 15.5, 9.0, 6.5 Hz, 1H), 1.44 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 149.6, 143.8, 136.1, 136.0, 129.4, 129.0, 128.5, 128.0, 127.9, 126.8, 126.7, 125.0, 116.7, 112.8, 65.1, 45.7, 43.2, 27.2, 18.7. (**3s''**): ¹H NMR (500 MHz, CDCl₃): δ 7.24–7.20 (m, 2H), 7.18–7.12 (m, 7H), 7.10–7.07 (m, 1H), 6.91 (d, *J* = 7.5 Hz, 1H), 6.80 (d, *J* = 8.0 Hz, 2H), 6.66 (t, *J* = 7.3 Hz, 1H), 4.86 (d, *J* = 7.0 Hz, 1H), 3.58 (ddd, *J* = 12.5, 6.5, 6.0 Hz, 1H), 3.46–3.37 (m, 2H), 3.00–2.89 (m, 2H), 1.32 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 150.1, 144.3, 136.8, 135.6, 129.1, 128.8, 128.5, 128.12, 128.10, 126.8, 126.4, 125.3, 117.2, 114.1, 65.0, 45.0, 42.9, 27.2, 18.6.

Spectra data were identical to the literature.^[10b and 10d]



1-(*tert*-butyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3t**). **3t** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2t** (92.4 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=5:1) afforded **3t** (30.3 mg, 57% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.23–7.21 (m, 2H), 7.20–7.16 (m, 2H), 7.14–7.10 (m, 2H), 6.93 (d, *J* = 8.0 Hz, 2H), 6.68 (t, *J* = 7.0 Hz, 1H), 4.68 (s, 1H), 3.88 (dt, *J* = 12.5, 6.5 Hz, 1H), 3.55 (dt, *J* = 12.5, 7.0 Hz, 1H), 3.07 (dt, *J* = 16.0, 7.0 Hz, 1H), 2.99 (dt, *J* = 16.5, 6.8 Hz, 1H), 1.03 (s, 9H); ¹³C NMR (126 MHz, CDCl₃): δ 151.3, 137.2, 135.6, 129.1, 128.9, 128.5, 126.7, 125.2, 116.8, 114.3, 66.2, 44.1, 39.3, 29.4, 27.4.


Spectra data were identical to the literature.^[9b and 12]



1-(*tert*-pentyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3u**). **3u** was prepared according to the


general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2u** (95.8 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=5:1) afforded **3u** (24.6 mg, 44% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.22–7.15 (m, 4H), 7.12 (t, *J* = 6.8 Hz, 2H), 6.92 (d, *J* = 8.5 Hz, 2H), 6.68 (t, *J* = 7.3 Hz, 1H), 4.71 (s, 1H), 3.88 (dt, *J* = 12.5, 7.0 Hz, 1H), 3.61 (dt, *J* = 13.0, 6.5 Hz, 1H), 3.05–2.96 (m, 2H), 1.49 (q, *J* = 7.5 Hz, 2H), 0.95 (s, 3H), 0.94 (s, 3H), 0.90 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 151.6, 137.2, 135.7, 129.1, 128.8, 128.6, 126.6, 125.1, 117.0, 114.7, 65.1, 44.1, 41.8, 33.4, 27.1, 26.1, 24.8, 8.9.

Spectra data were identical to the literature.^[9b]



1-(1-methylcyclohexyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3v**). **3v** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2v** (102.0 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=5:1) afforded **3v** (44.0 mg, 72% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.23–7.16 (m, 4H), 7.14–7.11 (m, 2H), 6.95 (d, *J* = 8.0 Hz, 2H), 6.69 (t, *J* = 7.3 Hz, 1H), 4.67 (s, 1H), 3.89 (dt, *J* = 13.0, 6.5 Hz, 1H), 3.60 (dt, *J* = 12.5, 7.0 Hz, 1H), 3.05 (dt, *J* = 16.5, 7.0 Hz, 1H), 2.99 (dt, *J* = 16.5, 7.0 Hz, 1H), 1.55–1.36 (m, 9H), 1.18–1.08 (m, 1H), 0.96 (s, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 151.6, 137.0, 135.7, 129.1, 129.0, 128.5, 126.6, 125.1, 116.9, 114.7, 67.0, 44.5, 41.9, 36.9, 36.1, 27.2, 26.2, 22.5, 22.1, 21.5.


Spectra data were identical to the literature.^[9b and 12]




1-(adamantan-1-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3w**). **3w** was prepared according to the general procedure, using **1a** (41.9 mg, 0.20 mmol) and **2w** (111.2 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (PE/DCM=5:1) afforded **3w** (66.0 mg, 96% yield) as a white syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.23 (t, *J* = 8.0 Hz, 2H), 7.20–7.11 (m, 4H), 6.96 (d, *J* = 8.5 Hz, 2H), 6.69 (t, *J* = 7.0 Hz, 1H), 4.57 (s, 1H), 3.93 (ddd, *J* = 11.8, 6.8, 5.0 Hz, 1H), 3.48 (dt, *J* = 11.5, 8.0 Hz, 1H), 3.18 (dt, *J* = 16.0, 8.0 Hz, 1H), 2.97 (ddd, *J* = 16.0, 6.5, 5.0

Hz, 1H), 1.95 (s, 3H), 1.76 (d, $J = 11.5$ Hz, 3H), 1.66–1.57 (m, 9H); ^{13}C NMR (126 MHz, CDCl_3): δ 151.4, 136.3, 135.7, 129.2, 129.0, 128.2, 126.7, 125.1, 116.4, 113.9, 67.1, 45.3, 41.5, 41.0, 37.0, 29.0, 27.9.

Spectra data were identical to the literature.^[9b]




2-(4-ethylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4b**). **4b** was prepared according to the general procedure, using **1b** (47.5 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4b** (57.2 mg, 89% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.20–7.12 (m, 3H), 7.07 (d, $J = 8.5$ Hz, 3H), 6.83 (d, $J = 9.0$ Hz, 2H), 4.39 (d, $J = 8.5$ Hz, 1H), 4.03–3.96 (m, 2H), 3.73 (ddd, $J = 12.5, 7.0, 6.0$ Hz, 1H), 3.53 (dt, $J = 12.5, 6.3$ Hz, 1H), 3.34 (td, $J = 12.0, 2.0$ Hz, 1H), 3.25 (td, $J = 11.5, 2.5$ Hz, 1H), 3.03 (dt, $J = 16.5, 6.8$ Hz, 1H), 2.94 (dt, $J = 16.0, 6.5$ Hz, 1H), 2.56 (q, $J = 7.5$ Hz, 2H), 2.02–1.96 (m, 1H), 1.91–1.87 (m, 1H), 1.60–1.47 (m, 3H), 1.20 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 148.2, 137.0, 135.3, 132.9, 128.7, 128.6, 128.4, 126.9, 125.4, 113.9, 68.5, 68.1, 63.6, 43.0, 41.6, 31.1, 31.0, 27.8, 27.0, 16.0; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{28}\text{NO}$ 322.2165, found 322.2170.




2-([1,1'-biphenyl]-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4c**). **4c** was prepared according to the general procedure, using **1c** (57.1 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4c** (59.1 mg, 80% yield) as a white syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.56 (d, $J = 7.5$ Hz, 2H), 7.51 (d, $J = 8.5$ Hz, 2H), 7.41 (t, $J = 7.5$ Hz, 2H), 7.28 (d, $J = 7.5$ Hz, 1H), 7.23–7.16 (m, 3H), 7.11 (d, $J = 7.0$ Hz, 1H), 6.96 (d, $J = 8.5$ Hz, 2H), 4.52 (d, $J = 8.5$ Hz, 1H), 4.05–3.98 (m, 2H), 3.79 (dt, $J = 12.0, 6.5$ Hz, 1H), 3.59 (d, $J = 12.5, 6.8$ Hz, 1H), 3.35 (t, $J = 11.5$ Hz, 1H), 3.26 (td, $J = 11.5, 2.5$ Hz, 1H), 3.11–3.00 (m, 2H), 2.09–1.98 (m, 1H), 1.89 (d, $J = 13.5$ Hz, 1H), 1.64–1.49 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.3, 141.1, 136.8, 135.2, 129.7, 128.8, 128.6, 128.4,


127.9, 127.1, 126.4, 126.2, 125.5, 113.6, 68.4, 68.0, 63.4, 43.0, 41.6, 31.05, 31.01, 27.3; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{26}H_{28}NO$ 370.2165, found 370.2166.




2-(4-fluorophenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4d**). **4d** was prepared according to the general procedure, using **1d** (45.5 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4d** (54.2 mg, 87% yield) as a colorless oil. 1H NMR (500 MHz, $CDCl_3$): δ 7.21–7.14 (m, 3H), 7.09–7.07 (m, 1H), 6.94–6.89 (m, 2H), 6.82–6.78 (m, 2H), 4.28 (d, $J = 9.0$ Hz, 1H), 4.03–3.96 (m, 2H), 3.71 (ddd, $J = 12.8, 7.3, 6.0$ Hz, 1H), 3.50 (dt, $J = 13.0, 6.0$ Hz, 1H), 3.34 (td, $J = 11.8, 2.0$ Hz, 1H), 3.25 (td, $J = 11.8, 2.5$ Hz, 1H), 3.00 (dt, $J = 16.5, 6.8$ Hz, 1H), 2.91 (dt, $J = 16.5, 6.0$ Hz, 1H), 2.00–1.92 (m, 1H), 1.89–1.85 (m, 1H), 1.59–1.43 (m, 3H); ^{13}C NMR (126 MHz, $CDCl_3$): δ 155.7 (d, $J = 236.6$ Hz), 146.9 (d, $J = 1.9$ Hz), 136.7, 135.1, 128.8, 128.4, 127.0, 125.5, 115.6 (d, $J = 22.1$ Hz), 115.4 (d, $J = 7.3$ Hz), 68.4, 68.0, 64.0, 43.4, 41.5, 31.1, 31.0, 26.7; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{20}H_{23}FNO$ 312.1758, found 312.1764.




2-(4-chlorophenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4e**). **4e** was prepared according to the general procedure, using **1e** (48.7 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4e** (45.9 mg, 70% yield) as a colorless oil. 1H NMR (500 MHz, $CDCl_3$): δ 7.22–7.14 (m, 5H), 7.09–7.06 (m, 1H), 6.80–6.77 (m, 2H), 4.37 (d, $J = 9.0$ Hz, 1H), 4.02–3.95 (m, 2H), 3.71 (dt, $J = 12.0, 6.3$ Hz, 1H), 3.48 (dt, $J = 12.0, 7.0$ Hz, 1H), 3.32 (td, $J = 12.0, 2.0$ Hz, 1H), 3.23 (td, $J = 11.5, 2.5$ Hz, 1H), 3.05–2.95 (m, 2H), 2.00–1.92 (m, 1H), 1.83–1.80 (m, 1H), 1.57–1.47 (m, 3H); ^{13}C NMR (126 MHz, $CDCl_3$): δ 148.6, 136.6, 135.0, 129.0, 128.7, 128.3, 127.2, 125.6, 121.7, 114.7, 68.4, 68.0, 63.5, 43.1, 41.6, 31.03, 30.99, 27.1; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{20}H_{23}ClNO$ 328.1463, found 328.1468.



2-(4-bromophenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4f**). **4f** was prepared according to the general procedure, using **1f** (57.6 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4f** (59.6 mg, 80% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.30–7.27 (m, 2H), 7.22–7.14 (m, 3H), 7.07 (dd, *J* = 7.0, 2.0 Hz, 1H), 6.75–6.72 (m, 2H), 4.37 (d, *J* = 8.5 Hz, 1H), 4.01–3.95 (m, 2H), 3.70 (dt, *J* = 12.5, 6.0 Hz, 1H), 3.47 (dt, *J* = 12.5, 6.8 Hz, 1H), 3.31 (td, *J* = 11.8, 2.0 Hz, 1H), 3.23 (td, *J* = 11.5, 2.5 Hz, 1H), 3.05–2.96 (m, 2H), 1.99–1.91 (m, 1H), 1.83–1.78 (m, 1H), 1.56–1.43 (m, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 149.0, 136.6, 135.0, 131.9, 128.6, 128.3, 127.2, 125.6, 115.1, 108.8, 68.4, 68.0, 63.4, 43.1, 41.6, 31.02, 30.99, 27.1; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₀H₂₃BrNO 372.0958, found 372.0955.




2-(4-methoxyphenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4g**). **4g** was prepared according to the general procedure, using **1g** (47.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4g** (34.9 mg, 54% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.18–7.11 (m, 3H), 7.09–7.06 (m, 1H), 6.83–6.77 (m, 4H), 4.23 (d, *J* = 8.5 Hz, 1H), 4.02–3.95 (m, 2H), 3.73 (s, 3H), 3.69 (ddd, *J* = 12.5, 8.0, 5.5 Hz, 1H), 3.50 (dt, *J* = 13.0, 6.0 Hz, 1H), 3.33 (td, *J* = 11.5, 1.5 Hz, 1H), 3.24 (td, *J* = 11.8, 2.5 Hz, 1H), 2.97 (ddd, *J* = 16.5, 7.5, 6.5 Hz, 1H), 2.84 (dt, *J* = 16.5, 6.0 Hz, 1H), 1.99–1.89 (m, 2H), 1.55–1.42 (m, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 152.1, 145.0, 136.9, 135.3, 128.9, 128.5, 126.8, 125.3, 116.3, 114.8, 68.5, 68.1, 64.2, 55.9, 43.6, 41.5, 31.2, 31.1, 26.6; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₁H₂₆NO₂ 324.1958, found 324.1963.




1-(tetrahydro-2*H*-pyran-4-yl)-2-(*m*-tolyl)-1,2,3,4-tetrahydroisoquinoline (**4h**). **4h** was prepared according to the general procedure, using **1h** (44.7 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol)

as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4h** (52.3 mg, 85% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.20–7.07 (m, 5H), 6.70–6.69 (m, 2H), 6.55 (d, *J* = 7.5 Hz, 1H), 4.44 (d, *J* = 8.5 Hz, 1H), 4.02–3.96 (m, 2H), 3.72 (dt, *J* = 12.5, 6.5 Hz, 1H), 3.54 (dt, *J* = 12.5, 6.5 Hz, 1H), 3.33 (td, *J* = 12.0, 2.0 Hz, 1H), 3.24 (td, *J* = 11.5, 2.5 Hz, 1H), 3.04 (dt, *J* = 16.0, 6.5 Hz, 1H), 2.97 (td, *J* = 16.0, 6.5 Hz, 1H), 2.32 (s, 3H), 2.01–1.94 (m, 1H), 1.88–1.84 (m, 1H), 1.59–1.47 (m, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 150.1, 139.0, 137.0, 135.3, 129.2, 128.6, 128.4, 127.0, 125.4, 118.0, 114.3, 110.7, 68.5, 68.0, 63.3, 42.9, 41.6, 31.1, 31.0, 27.2, 22.1; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₁H₂₆NO 308.2009, found 308.2017.




2-(3-chlorophenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4i**). **4i** was prepared according to the general procedure, using **1i** (48.7 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4i** (59.0 mg, 90% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.22–7.15 (m, 3H), 7.08–7.05 (m, 2H), 6.98 (t, *J* = 1.8 Hz, 1H), 6.81 (dd, *J* = 7.5, 1.0 Hz, 1H), 6.78 (dd, *J* = 8.5, 2.5 Hz, 1H), 4.41 (d, *J* = 9.0 Hz, 1H), 4.02–3.96 (m, 2H), 3.70 (dt, *J* = 12.0, 6.3 Hz, 1H), 3.47 (dt, *J* = 12.5, 7.0 Hz, 1H), 3.32 (td, *J* = 11.8, 2.0 Hz, 1H), 3.23 (td, *J* = 11.5, 3.0 Hz, 1H), 3.03 (t, *J* = 6.8 Hz, 2H), 2.00–1.92 (m, 1H), 1.81–1.78 (m, 1H), 1.57–1.46 (m, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 151.1, 136.6, 134.9, 130.5, 128.6, 128.3, 127.3, 125.7, 123.6, 119.6, 116.0, 111.8, 68.3, 67.9, 63.3, 43.0, 41.6, 31.0, 30.9, 27.2; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₀H₂₃ClNO 328.1463, found 328.1466.




2-(3-bromophenyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4j**). **4j** was prepared according to the general procedure, using **1j** (57.6 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4j** (52.9 mg, 71% yield) as a colorless syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.23–7.15

(m, 3H), 7.12 (t, $J = 8.3$ Hz, 1H), 7.08 (d, $J = 7.5$ Hz, 1H), 6.82 (t, $J = 7.0$ Hz, 1H), 6.74 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.67 (dd, $J = 7.0, 2.0$ Hz, 1H), 4.41 (d, $J = 9.0$ Hz, 1H), 4.02–3.96 (m, 2H), 3.71 (dt, $J = 12.0, 6.0$ Hz, 1H), 3.48 (dt, $J = 12.0, 7.0$ Hz, 1H), 3.32 (td, $J = 12.0, 2.0$ Hz, 1H), 3.23 (td, $J = 11.5, 3.0$ Hz, 1H), 3.03 (t, $J = 6.8$ Hz, 2H), 2.00–1.92 (m, 1H), 1.82–1.78 (m, 1H), 1.57–1.45 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 151.0, 136.6, 135.2, 134.9, 130.2, 128.6, 128.3, 127.3, 125.7, 116.7, 113.1, 111.4, 68.4, 68.0, 63.4, 43.1, 41.6, 31.0, 30.9, 27.2; HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{20}\text{H}_{23}\text{BrNO}$ 372.0958, found 372.0952.




2-(naphthalen-1-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4k**). **4k** was prepared according to the general procedure, using **1k** (51.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4k** (56.3 mg, 82% yield) as a white syrup. ^1H NMR (500 MHz, CDCl_3): δ 8.31 (d, $J = 8.0$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.54–7.47 (m, 3H), 7.25–7.20 (m, 4H), 7.14–7.12 (m, 1H), 6.87 (d, $J = 7.0$ Hz, 1H), 4.17 (d, $J = 7.5$ Hz, 1H), 4.05 (dd, $J = 11.0, 4.0$ Hz, 1H), 3.98 (dt, $J = 11.0, 2.5$ Hz, 1H), 3.78 (ddd, $J = 13.8, 10.8, 4.5$ Hz, 1H), 3.55 (ddd, $J = 13.8, 6.3, 2.5$ Hz, 1H), 3.42–3.37 (m, 1H), 3.34–3.29 (m, 1H), 2.75 (ddd, $J = 16.5, 10.5, 6.0$ Hz, 1H), 2.61 (dt, $J = 16.0, 3.0$ Hz, 1H), 2.12–2.05 (m, 2H), 1.66–1.51 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.5, 137.2, 135.7, 135.1, 129.6, 129.4, 128.6, 128.3, 126.6, 125.91, 125.85, 125.54, 125.45, 124.2, 123.4, 118.5, 68.7, 68.3, 66.0, 46.4, 42.2, 31.5, 31.0, 25.8; HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{24}\text{H}_{26}\text{NO}$ 344.2009, found 344.2014.




2-(naphthalen-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4l**). **4l** was prepared according to the general procedure, using **1l** (51.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4l** (52.9 mg, 77% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.71 (d, $J = 9.0$ Hz, 1H), 7.68 (d, $J = 8.5$ Hz, 1H), 7.38–7.35 (m, 1H), 7.31 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.23–7.14 (m,

5H), 7.06 (d, $J = 2.5$ Hz, 1H), 4.60 (d, $J = 9.0$ Hz, 1H), 4.02–3.99 (m, 2H), 3.84 (dt, $J = 13.0, 6.5$ Hz, 1H), 3.73 (dt, $J = 13.0, 6.5$ Hz, 1H), 3.35 (td, $J = 11.8, 2.0$ Hz, 1H), 3.27 (td, $J = 11.5, 3.0$ Hz, 1H), 3.10 (dt, $J = 16.5, 6.5$ Hz, 1H), 3.02 (dt, $J = 16.5, 6.5$ Hz, 1H), 2.08–2.00 (m, 1H), 1.91–1.87 (m, 1H), 1.62–1.53 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 147.8, 136.9, 135.1, 128.9, 128.8, 128.4, 127.4, 127.14, 127.08, 126.4, 126.3, 125.5, 122.4, 117.2, 107.7, 68.4, 68.0, 63.4, 42.9, 41.5, 31.2, 31.1, 27.1; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{26}\text{NO}$ 344.2009, found 344.2013.




2-([1,1'-biphenyl]-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4m**). **4m** was prepared according to the general procedure, using **1m** (57.1 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4m** (6.7 mg, 9% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.49 (d, $J = 7.0$ Hz, 2H), 7.37 (t, $J = 7.5$ Hz, 2H), 7.29 (t, $J = 7.3$ Hz, 1H), 7.18 (dd, $J = 7.5, 1.5$ Hz, 1H), 7.16–7.11 (m, 2H), 7.08 (td, $J = 7.8, 1.3$ Hz, 1H), 7.03–6.96 (m, 3H), 6.86 (d, $J = 8.0$ Hz, 1H), 4.00 (dd, $J = 11.3, 4.3$ Hz, 1H), 3.94–3.90 (m, 2H), 3.30–3.25 (m, 1H), 3.22–3.15 (m, 2H), 3.13–3.09 (m, 1H), 2.65 (ddd, $J = 16.8, 10.3, 7.0$ Hz, 1H), 2.48 (ddd, $J = 16.8, 5.3, 2.5$ Hz, 1H), 1.89–1.81 (m, 2H), 1.54–1.51 (m, 1H), 1.44–1.34 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.9, 142.3, 137.3, 135.7, 135.3, 132.0, 129.2, 129.1, 128.5, 128.4, 128.2, 126.7, 126.5, 125.2, 122.0, 121.0, 68.4, 68.1, 64.8, 43.7, 41.0, 31.3, 31.2, 25.9; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{28}\text{NO}$ 370.2165, found 370.2170.




2-(2,6-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4n**). **4n** was prepared according to the general procedure, using **1n** (53.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4n** (50.2 mg, 71% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.17–7.12 (m, 3H), 7.08–7.02 (m, 2H), 6.55 (d, $J = 8.5$ Hz, 2H), 4.09 (d, $J = 6.5$ Hz, 1H), 3.93 (dd, $J = 11.0, 4.0$ Hz, 1H), 3.88 (dd, $J = 11.0, 4.0$ Hz, 1H), 3.71 (s, 6H), 3.41 (dt, $J = 11.0, 5.0$ Hz,

1H), 3.32–3.26 (m, 1H), 3.25–3.20 (m, 1H), 3.07 (ddd, $J = 10.8, 9.3, 4.0$ Hz, 1H), 2.96 (ddd, $J = 15.0, 9.0, 4.5$ Hz, 1H), 2.69 (dt, $J = 15.0, 4.8$ Hz, 1H), 1.83 (d, $J = 13.5$ Hz, 1H), 1.80–1.73 (m, 1H), 1.50–1.39 (m, 2H), 1.29–1.20 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 157.7, 139.0, 137.2, 130.3, 128.1, 127.9, 125.6, 125.0, 124.7, 105.1, 68.8, 68.6, 66.2, 55.7, 47.6, 43.8, 30.5, 30.4, 30.1; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{28}\text{NO}_3$ 354.2064, found 354.2067.




2-(3,4-dimethylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4o**). **4o** was prepared according to the general procedure, using **1o** (47.5 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4o** (47.6 mg, 74% yield) as a colorless syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.19–7.12 (m, 3H), 7.09–7.08 (m, 1H), 6.98 (d, $J = 8.5$ Hz, 1H), 6.71 (d, $J = 2.5$ Hz, 1H), 6.64 (dd, $J = 8.5, 2.5$ Hz, 1H), 4.38 (d, $J = 9.0$ Hz, 1H), 4.03–3.97 (m, 2H), 3.72 (ddd, $J = 12.5, 7.0, 6.5$ Hz, 1H), 3.55 (dt, $J = 12.5, 6.3$ Hz, 1H), 3.34 (td, $J = 12.0, 2.0$ Hz, 1H), 3.25 (td, $J = 11.8, 2.5$ Hz, 1H), 3.03 (dt, $J = 16.0, 6.8$ Hz, 1H), 2.92 (dt, $J = 16.0, 6.5$ Hz, 1H), 2.24 (s, 3H), 2.17 (s, 3H), 2.01–1.93 (m, 1H), 1.89 (d, $J = 13.5$ Hz, 1H), 1.60–1.47 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 148.4, 137.2, 137.0, 135.3, 130.3, 128.7, 128.4, 126.8, 125.3, 125.2, 115.6, 111.4, 68.5, 68.1, 63.4, 42.9, 41.5, 31.1, 31.0, 27.0, 20.6, 18.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{28}\text{NO}$ 322.2165, found 322.2171.




2-(3,4-dichlorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4p**). **4p** was prepared according to the general procedure, using **1p** (55.6 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=30:1) afforded **4p** (33.3 mg, 46% yield) as a colorless syrup. ^1H NMR (500 MHz, CDCl_3): δ 7.24–7.20 (m, 2H), 7.18–7.14 (m, 2H), 7.08 (dd, $J = 7.0, 2.0$ Hz, 1H), 6.90 (d, $J = 3.0$ Hz, 1H), 6.69 (dd, $J = 9.0, 3.0$ Hz, 1H), 4.36 (d, $J = 9.0$ Hz, 1H), 4.01–3.95 (m, 2H), 3.69 (dt, $J = 12.0, 6.0$ Hz, 1H), 3.44 (dt, $J = 12.0, 7.0$ Hz, 1H), 3.31 (td, $J = 11.8, 2.0$ Hz, 1H), 3.22 (td, $J = 11.5, 3.0$ Hz, 1H), 3.07–2.98 (m, 2H), 1.98–1.90 (m, 1H), 1.78–1.75 (m, 1H), 1.55–1.46 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3):

δ 149.4, 136.3, 134.7, 132.9, 130.5, 128.6, 128.3, 127.4, 125.8, 119.4, 114.6, 112.8, 68.3, 67.9, 43.3, 41.6, 31.00, 30.98, 27.1; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{20}H_{22}Cl_2NO$ 362.1073, found 362.1076.




2-(pyridin-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4q**). **4q** was prepared according to the general procedure, using **1q** (42.1 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4q** (35.3 mg, 60% yield) as a white syrup. 1H NMR (500 MHz, $CDCl_3$): δ 7.47–7.43 (m, 2H), 7.22–7.14 (m, 3H), 7.07–7.05 (m, 1H), 6.66–6.63 (m, 2H), 4.38 (d, $J = 9.0$ Hz, 1H), 4.01–3.94 (m, 2H), 3.69 (dt, $J = 12.0, 6.0$ Hz, 1H), 3.46 (dt, $J = 12.0, 7.0$ Hz, 1H), 3.31 (td, $J = 11.8, 2.0$ Hz, 1H), 3.22 (td, $J = 11.5, 3.0$ Hz, 1H), 3.01 (t, $J = 6.5$ Hz, 2H), 1.99–1.91 (m, 1H), 1.81–1.77 (m, 1H), 1.56–1.45 (m, 3H); ^{13}C NMR (126 MHz, $CDCl_3$): δ 149.5, 137.8, 136.6, 135.0, 128.6, 128.3, 127.2, 125.7, 115.6, 68.4, 68.0, 63.3, 43.0, 41.6, 31.02, 30.98, 27.2; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{19}H_{23}N_2O$ 295.1805, found 295.1807.




6,7-dimethoxy-2-phenyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline (**4r**). **4r** was prepared according to the general procedure, using **1r** (53.9 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4r** (50.2 mg, 71% yield) as a colorless oil. 1H NMR (500 MHz, $CDCl_3$): δ 7.24–7.20 (m, 2H), 6.88 (d, $J = 8.5$ Hz, 2H), 6.71 (t, $J = 7.3$ Hz, 1H), 6.65 (s, 1H), 6.59 (s, 1H), 4.34 (d, $J = 8.5$ Hz, 1H), 4.02–3.97 (m, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.69 (ddd, $J = 12.8, 7.8, 6.0$ Hz, 1H), 3.56 (dt, $J = 12.5, 6.5$ Hz, 1H), 3.34 (td, $J = 12.0, 2.0$ Hz, 1H), 3.27 (td, $J = 11.8, 2.0$ Hz, 1H), 2.96 (dt, $J = 16.0, 6.8$ Hz, 1H), 2.84 (dt, $J = 16.5, 6.3$ Hz, 1H), 1.98 (ddt, $J = 20.0, 12.0, 3.9$ Hz, 1H), 1.87 (ddd, $J = 13.5, 3.0, 1.5$ Hz, 1H), 1.64–1.60 (m, 1H), 1.57–1.47 (m, 2H); ^{13}C NMR (126 MHz, $CDCl_3$): δ 150.1, 148.0, 146.6, 129.3, 128.9, 127.3, 117.2, 113.9, 112.0, 111.7, 68.5, 68.0, 63.1, 56.3, 56.0, 42.6, 41.6, 31.2, 31.1, 26.5; HRMS (ESI-TOF) m/z $[M + H]^+$ calcd for $C_{22}H_{28}NO_3$

354.2064, found 354.2072.




2-(4-fluorophenyl)-6,7-dimethoxy-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline

(**4s**). **4s** was prepared according to the general procedure, using **1s** (57.5 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4s** (40.1 mg, 54% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 6.92–6.87 (m, 2H), 6.81–6.77 (m, 2H), 6.62 (s, 1H), 6.58 (s, 1H), 4.16 (d, $J = 8.5$ Hz, 1H), 3.99 (td, $J = 11.5, 3.5$ Hz, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.66 (ddd, $J = 13.0, 8.5, 5.5$ Hz, 1H), 3.52 (dt, $J = 13.0, 6.0$ Hz, 1H), 3.33 (td, $J = 11.8, 2.0$ Hz, 1H), 3.26 (td, $J = 12.0, 2.5$ Hz, 1H), 2.90 (ddd, $J = 16.5, 8.8, 6.3$ Hz, 1H), 2.75 (dt, $J = 16.5, 5.5$ Hz, 1H), 1.99–1.91 (m, 1H), 1.90–1.86 (m, 1H), 1.63–1.59 (m, 1H), 1.54–1.43 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 155.8 (d, $J = 237.0$ Hz), 148.0, 147.0 (d, $J = 1.9$ Hz), 146.6, 128.5, 127.1, 116.0 (d, $J = 7.3$ Hz), 115.6 (d, $J = 21.9$ Hz), 111.9, 111.8, 68.5, 68.0, 63.8, 56.3, 56.0, 43.3, 41.5, 31.3, 31.1, 25.9; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{27}\text{FNO}_3$ 372.1969, found 372.1973.




2-(4-chlorophenyl)-6,7-dimethoxy-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinoline


(**4t**). **4t** was prepared according to the general procedure, using **1t** (60.8 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=20:1) afforded **4t** (52.0 mg, 67% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.15–7.12 (m, 2H), 6.79–6.76 (m, 2H), 6.64 (s, 1H), 6.58 (s, 1H), 4.25 (d, $J = 8.5$ Hz, 1H), 4.01–3.96 (m, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.66 (ddd, $J = 12.5, 7.3, 5.8$ Hz, 1H), 3.50 (dt, $J = 12.5, 6.5$ Hz, 1H), 3.32 (td, $J = 11.8, 2.0$ Hz, 1H), 3.25 (td, $J = 11.8, 2.0$ Hz, 1H), 2.93 (dt, $J = 16.0, 7.0$ Hz, 1H), 2.84 (dt, $J = 16.0, 6.0$ Hz, 1H), 1.99–1.91 (m, 1H), 1.84–1.80 (m, 1H), 1.60–1.57 (m, 1H), 1.53–1.44 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 148.8, 148.1, 146.7, 129.0, 128.5, 127.0, 121.9, 115.1, 111.9, 111.7, 68.4, 68.0, 63.3, 56.3, 56.0, 42.9, 41.6, 31.2, 31.1, 26.3; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{27}\text{ClNO}_3$ 388.1674, found 388.1673.



4-(1-isopropyl-3,4-dihydroisoquinolin-2(1*H*)-yl)benzaldehyde (**4u**). **4u** was prepared according to the general procedure, using **1u** (47.5 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=40:1) afforded **4u** (24.0 mg, 43% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 9.73 (s, 1H), 7.75–7.72 (m, 2H), 7.23–7.18 (m, 3H), 7.14–7.12 (m, 1H), 6.89 (d, *J* = 9.0 Hz, 2H), 4.59 (d, *J* = 8.5 Hz, 1H), 3.81 (ddd, *J* = 11.5, 6.5, 4.5 Hz, 1H), 3.52 (ddd, *J* = 12.0, 10.0, 6.0 Hz, 1H), 3.18 (ddd, *J* = 16.0, 9.5, 6.5 Hz, 1H), 3.03 (ddd, *J* = 15.5, 6.0, 5.0 Hz, 1H), 2.18–2.09 (m, 1H), 1.05 (d, *J* = 7.0 Hz, 3H), 0.96 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 190.3, 154.2, 137.3, 134.7, 132.1, 128.21, 128.20, 127.4, 126.0, 125.4, 111.7, 64.5, 43.7, 34.6, 27.8, 20.7, 20.3; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₁₉H₂₂NO 280.1696, found 280.1703.




1-(4-(1-isopropyl-3,4-dihydroisoquinolin-2(1*H*)-yl)phenyl)ethan-1-one (**4v**). **4v** was prepared according to the general procedure, using **1v** (50.3 mg, 0.20 mmol) and **2q** (99.1 mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=40:1) afforded **4v** (21.7 mg, 37% yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.88–7.86 (m, 2H), 7.23–7.16 (m, 3H), 7.13–7.12 (m, 1H), 6.85–6.82 (m, 2H), 4.56 (d, *J* = 8.5 Hz, 1H), 3.79 (ddd, *J* = 11.5, 6.5, 5.0 Hz, 1H), 3.51 (ddd, *J* = 11.5, 9.5, 6.0 Hz, 1H), 3.16 (ddd, *J* = 16.0, 9.5, 6.5 Hz, 1H), 3.02 (dt, *J* = 16.0, 5.0 Hz, 1H), 2.50 (s, 3H), 2.18–2.09 (m, 1H), 1.05 (d, *J* = 7.0 Hz, 3H), 0.96 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 196.3, 153.1, 137.4, 134.8, 130.7, 128.2, 127.2, 125.8, 125.5, 111.3, 64.3, 43.5, 34.6, 27.7, 26.1, 20.7, 20.2; HRMS (ESI-TOF) *m/z* [M + H]⁺ calcd for C₂₀H₂₄NO 294.1852, found 294.1857.



9-methyl-2-phenyl-1-(tetrahydro-2*H*-pyran-4-yl)-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-*b*]indole (**4w**). **4w** was prepared according to the general procedure, using **1w** (52.5 mg, 0.20 mmol) and **2q** (99.1

mg, 0.24 mmol) as starting materials. Purification using silica gel column chromatography (DCM/EA=50:1) afforded **4w** (47.2 mg, 68% yield) as a colorless oil. ^1H NMR (500 MHz, CDCl_3): δ 7.47 (d, $J = 8.0$ Hz, 1H), 7.28 (d, $J = 8.0$ Hz, 1H), 7.22–7.16 (m, 3H), 7.09 (t, $J = 7.3$ Hz, 1H), 6.93 (d, $J = 8.0$ Hz, 2H), 6.75 (t, $J = 7.0$ Hz, 1H), 4.49 (d, $J = 9.0$ Hz, 1H), 4.08–4.02 (m, 2H), 3.96 (dd, $J = 14.5, 6.3$ Hz, 1H), 3.78 (ddd, $J = 14.5, 11.5, 5.0$ Hz, 1H), 3.70 (s, 3H), 3.43–3.37 (m, 1H), 3.32 (td, $J = 11.8, 1.5$ Hz, 1H), 3.11–3.04 (m, 1H), 2.72 (dd, $J = 16.0, 5.5$ Hz, 1H), 2.27–2.20 (m, 1H), 2.01 (d, $J = 13.5$ Hz, 1H), 1.75 (qd, $J = 12.0, 4.5$ Hz, 1H), 1.65–1.59 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 151.2, 137.8, 136.2, 129.3, 127.2, 121.6, 119.3, 118.9, 118.2, 116.5, 109.2, 108.2, 68.6, 68.2, 59.3, 41.9, 41.4, 31.5, 31.3, 31.1, 19.3; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{27}\text{N}_2\text{O}$ 347.2118, found 347.2122.


7. Unsuccessful Substrates



8. Mechanistic Studies


8.1 Radical trapping experiments

(1)



A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (41.9 mg, 0.20 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2q** (99.1 mg, 0.24 mmol) and TEMPO (78.1 mg, 0.50 mmol) under air. The tube was evacuated and backfilled with N₂ for 3 times (3 × 5 min). Degassed DMF (2.0 mL) was added by syringe under N₂. The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. No desired alkylation product **3q** was observed by ¹H NMR spectroscopy of crude reaction mixture.


(2)




A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (41.9 mg, 0.20 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2q** (99.1 mg, 0.24 mmol) and BHT (110.2 mg, 0.50 mmol) under air. The tube was evacuated and backfilled with N₂ for 3 times (3 × 5 min). Degassed DMF (2.0 mL) was added by syringe under N₂. The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium

hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (DCM/EA=30:1) to give 44.6 mg (76%) of **3q** as a colorless oil.

(3)



A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (41.9 mg, 0.20 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2q** (99.1 mg, 0.24 mmol) and 1,1-diphenylethylene (89.0 μL , 0.50 mmol) under air. The tube was evacuated and backfilled with N_2 for 3 times (3×5 min). Degassed DMF (2.0 mL) was added by syringe under N_2 . The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (DCM/EA=30:1) to give 64.4 mg (68%) of **5** as a colorless oil and 11.7 mg (20%) of **3q** as a white syrup.




1-(1,1-diphenyl-2-(tetrahydro-2*H*-pyran-4-yl)ethyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**5**).


$^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.54 (s, 2H), 7.32 (t, $J = 7.8$ Hz, 2H), 7.28–7.20 (m, 3H), 7.11 (t, $J = 7.8$ Hz, 2H), 7.07–7.03 (m, 4H), 6.87–6.77 (m, 5H), 6.05 (s, 1H), 3.77 (dd, $J = 11.8, 3.3$ Hz, 1H), 3.45 (dt, $J = 11.0, 2.8$ Hz, 1H), 3.28 (ddd, $J = 13.0, 7.0, 4.5$ Hz, 1H), 3.18 (dt, $J = 11.3, 2.3$ Hz, 1H), 3.01 (ddd, $J = 13.5, 9.0, 6.0$ Hz, 1H), 2.79 (td, $J = 11.8, 2.0$ Hz, 1H), 2.70 (dd, $J = 14.8, 1.3$ Hz, 1H),

2.55–2.49 (m, 1H), 1.96 (dd, $J = 14.8, 1.3$ Hz), 1.50 (dt, $J = 11.5, 5.0$ Hz, 1H), 1.43–1.39 (m, 1H), 1.37–1.26 (m, 3H), 0.79–0.71 (m, 1H), -0.11 (d, $J = 13.0$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 152.4, 145.7, 141.7, 136.9, 131.4, 130.0, 129.4, 128.7, 128.1, 127.9, 127.0, 126.8, 126.6, 126.5, 125.0, 118.4, 116.6, 68.3, 68.1, 66.2, 60.5, 46.5, 43.4, 35.3, 34.5, 32.2, 25.5; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{34}\text{H}_{36}\text{NO}$ 474.2791, found 474.2795.

8.2 Radical clock experiment



A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (41.9 mg, 0.20 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2x** (91.9 mg, 0.24 mmol) under air. The tube was evacuated and backfilled with N_2 for 3 times (3×5 min). Degassed DMF (2.0 mL) was added by syringe under N_2 . The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M), water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (PE/DCM=3:1) to give 22.7 mg (43%) of homoallylation product **3x** as a colorless oil.




1-(but-3-en-1-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (**3x**). ^1H NMR (500 MHz, CDCl_3): δ 7.26–7.22 (m, 2H), 7.19–7.12 (m, 4H), 6.89 (d, $J = 8.5$ Hz, 2H), 6.73 (t, $J = 7.3$ Hz, 1H), 5.92–5.84 (m, 1H), 5.08–5.00 (m, 2H), 4.70 (t, $J = 7.0$ Hz, 1H), 3.67–3.59 (m, 2H), 3.04 (dt, $J = 16.0, 7.0$ Hz, 1H), 2.84 (dt, $J = 16.0, 5.0$ Hz, 1H), 2.28–2.15 (m, 2H), 2.12–2.04 (m, 1H), 1.86–1.79 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.8, 139.0, 138.5, 135.2, 129.4, 128.7, 127.5, 126.6, 125.9, 117.3, 115.1, 114.1, 58.6, 41.9, 35.9, 31.0, 27.0.


Spectra data were identical to the literature.^[12]

8.3 UV-visible spectroscopic measurements

UV-visible absorption spectra of *N*-phenyl tetrahydroisoquinoline **1a** (0.10 M), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2q** (0.10 M), and equimolar mixture of **1a** and **2q** (0.10 M) in DMF were recorded using UV/vis spectrometer.




9. Byproduct Analysis



A 10-mL Schlenk Storage Tube equipped with magnetic stir bar was charged with *N*-aryl tetrahydroisoquinoline **1a** (41.9 mg, 0.20 mmol), redox-active tetrachloro-*N*-hydroxyphthalimide ester **2t** (192.5 mg, 0.50 mmol) under air. The tube was evacuated and backfilled with N₂ for 3 times (3 × 5 min). Degassed DMF (3.0 mL) was added by syringe under N₂. The resulting mixture was degassed by using a “freeze–pump–thaw” procedure for 3 times. The mixture was then irradiated by 3 W blue LEDs and stirred at room temperature for 24 hours. Upon completion, the reaction mixture was transferred to a separate funnel using 20.0 mL ethyl acetate and 5.0 mL water. The organic layer was separated and the aqueous layer extracted with 10.0 mL ethyl acetate. The combined organic extracts were successively washed with aqueous sodium hydroxide (0.10 M),

water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (PE/DCM, 5:1 to 3:1) to give the desired product **3t** (14.5 mg, 55%) as a colorless syrup and byproduct **6** (9.0 mg, 34%) as a colorless oil.



1-(*tert*-butyl)-2-phenyl-1,2-dihydroisoquinoline (**6**). ^1H NMR (500 MHz, CDCl_3): δ 7.30–7.27 (m, 2H), 7.20 (td, $J = 7.5, 1.5$ Hz, 1H), 7.14–7.06 (m, 4H), 7.00 (d, $J = 7.5$ Hz, 1H), 6.91 (t, $J = 7.3$ Hz, 1H), 6.73 (dd, $J = 7.0, 1.5$ Hz, 1H), 5.93 (d, $J = 7.5$ Hz, 1H), 4.83 (s, 1H), 0.95 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3): δ 147.9, 133.1, 130.6, 129.2, 128.4, 128.0, 127.2, 125.3, 123.3, 120.5, 117.1, 108.7, 68.2, 40.5, 27.8; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{22}\text{N}$ 264.1747, found 264.1748.

10. References

- (1) (a) F. Y. Kwong, A. Klapars and S. L. Buchwald, *Org. Lett.*, 2002, **4**, 581; (b) Z. Li and C.-J. Li, *J. Am. Chem. Soc.*, 2005, **127**, 6968.
- (2) (a) Y. Liu, C. Wang, D. Xue, M. Xiao, J. Liu, C. Li and J. Xiao, *Chem. – Eur. J.*, 2017, **23**, 3062; (b) Q. Xia, H. Tian, J. Dong, Y. Qu, L. Li, H. Song, Y. Liu and Q. Wang, *Chem. – Eur. J.*, 2018, **24**, 9269.
- (3) J. Almena, F. Foubelo and M. Yus, *Tetrahedron*, 1996, **52**, 8545.
- (4) A. Conejo-García, L. Pisani, M. del Carmen Núñez, M. Catto, O. Nicolotti, F. Leonetti, J. M. Campos, M. A. Gallo, A. Espinosa and A. Carotti, *J. Med. Chem.*, 2011, **54**, 2627.
- (5) (a) LUPIN LIMITED WO2009/109998, 2009, A1, Page/Page column 54; (b) G. Wei, C. Zhang, F. Bureš, X. Ye, C.-H. Tan and Z. Jiang, *ACS Catal.*, 2016, **6**, 3708; (c) J. Ye, J. Wu, T. Lv, G. Wu, Y. Gao and H. Chen, *Angew. Chem., Int. Ed.*, 2017, **56**, 14968; (d) Y.-Q. Huang, H.-J. Song, Y.-X. Liu and Q.-M. Wang, *Chem. – Eur. J.*, 2018, **24**, 2065.
- (6) (a) T. Qin, J. Cornella, C. Li, L. R. Malins, J. T. Edwards, S. Kawamura, B. D. Maxwell, M. D.

Eastgate and P. S. Baran, *Science*, 2016, **352**, 801; (b) A. Fawcett, J. Pradeilles, Y. Wang, T. Mutsuga, E. L. Myers and V. K. Aggarwal, *Science*, 2017, **357**, 283.

(7) G. Pandey, S. K. Tiwari and B. Singh, *Tetrahedron Lett.*, 2016, **57**, 4480.

(8) H. Tian, W. Xu, Y. Liu and Q. Wang, *Chem. Commun.*, 2019, **55**, 14813.


(9) (a) T. Wang, M. Schrempp, A. Berndhäuser, O. Schiemann and D. Menche, *Org. Lett.*, 2015, **17**, 3982; (b) W.-J. Zhou, G.-M. Cao, G. Shen, X.-Y. Zhu, Y.-Y. Gui, J.-H. Ye, L. Sun, L.-L. Liao, J. Li and D.-G. Yu, *Angew. Chem., Int. Ed.*, 2017, **56**, 15683.

(10) (a) J. P. Barham, M. P. John and J. A. Murphy, *Beilstein J. Org. Chem.*, 2014, **10**, 2981; (b) T. Ide, K. Shimizu, Y. Kawato, H. Egami and Y. Hamashima, *Heterocycles*, 2017, **95**, 738; (c) T. Wang and D.-H. Wang, *Org. Lett.*, 2019, **21**, 3981; (d) Z. Li, P. Ma, Y. Tan, Y. Liu, M. Gao, Y. Zhang, B. Yang, X. Huang, Y. Gao and J. Zhang, *Green Chem.*, 2020, **22**, 646; (e) D. Schönbauer, C. Sambiagio, T. Noël and M. Schnürch, *Beilstein J. Org. Chem.*, 2020, **16**, 809.



(11) Y. Xu, Z.-J. Xu, Z.-P. Liu and H. Lou, *Org. Chem. Front.*, 2019, **6**, 3902.



(12) L. Ren and H. Cong, *Org. Lett.*, 2018, **20**, 3225.



11. ^1H NMR and ^{13}C NMR Spectra




^1H NMR spectrum (CDCl_3 , 500 MHz) of **1n**
















^{13}C NMR spectrum (CDCl₃, 151 MHz) of **2a**







^1H NMR spectrum (CDCl₃, 600 MHz) of **2b**


































¹³C NMR spectrum (CDCl₃, 126 MHz) of **2p**




¹H NMR spectrum (CDCl₃, 500 MHz) of **2t**











¹³C NMR spectrum (CDCl₃, 126 MHz) of **2u**







¹H NMR spectrum (CDCl₃, 500 MHz) of **3a**


















^{13}C NMR spectrum (CDCl₃, 126 MHz) of **3g**




^1H NMR spectrum (CDCl₃, 500 MHz) of **3h**











¹³C NMR spectrum (CDCl₃, 126 MHz) of **3j**




¹H NMR spectrum (CDCl₃, 500 MHz) of **3k**












¹³C NMR spectrum (CDCl₃, 126 MHz) of **3o**





¹H NMR spectrum (CDCl₃, 500 MHz) of **3p**







^{13}C NMR spectrum (CDCl_3 , 126 MHz) of **3p**






^1H NMR spectrum (CDCl_3 , 500 MHz) of **3q**















^{13}C NMR spectrum (CDCl_3 , 126 MHz) of **3t**




^1H NMR spectrum (CDCl_3 , 500 MHz) of **3u**







¹³C NMR spectrum (CDCl₃, 126 MHz) of **3v**



¹H NMR spectrum (CDCl₃, 500 MHz) of **3w**



¹³C NMR spectrum (CDCl₃, 126 MHz) of **3w**



¹H NMR spectrum (CDCl₃, 500 MHz) of **4b**

